AHF urges Gilead to set initial price on latest HIV/AIDS drug combination

AIDS Healthcare Foundation (AHF) announced that California State Treasurer Bill Lockyer has sent a letter to California-based drug company, Gilead Sciences, Inc. urging the company to set an initial price on its latest HIV/AIDS drug combination—which is known as the ‘Quad’—that is “…sensitive to ongoing state budget difficulties,” and which will also “…provide the means to keep people with HIV/AIDS alive and as healthy as possible.”

See more here:
AHF urges Gilead to set initial price on latest HIV/AIDS drug combination

Share and Enjoy:
  • Print
  • Digg
  • StumbleUpon
  • Facebook
  • Yahoo! Buzz
  • Twitter
  • Google Bookmarks
  • Add to favorites
  • email
  • LinkedIn
  • RSS
  • Tumblr
Share